Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Hemophilia Market, by Distribution Channel
1.4.2 North America Hemophilia Market, by Type
1.4.3 North America Hemophilia Market, by Treatment Type
1.4.4 North America Hemophilia Market, by Therapy
1.4.5 North America Hemophilia Market, by Country
1.5 Methodology for the research
Chapter 2. Market At a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Trials and Approvals
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Product Launches and Product Expansions : 2017, Jun – 2021, Jun) Leading Players
4.4 Porter Five Forces Analysis
Chapter 5. North America Hemophilia Market by Distribution Channel
5.1 North America Specialty Pharmacies Market by Country
5.2 North America Hospital Pharmacies Market by Country
Chapter 6. North America Hemophilia Market by Type
6.1 North America Hemophilia A Market by Country
6.2 North America Hemophilia B Market by Country
6.3 North America Others Market by Country
Chapter 7. North America Hemophilia Market by Treatment Type
7.1 North America Prophylaxis Market by Country
7.2 North America On-demand Market by Country
7.3 North America Cure Market by Country
Chapter 8. North America Hemophilia Market by Therapy
8.1 North America Factor Replacement Therapy Market by Country
8.2 North America Hemophilia Market by Factor Replacement Therapy Type
8.2.1 North America Recombinant Factor Concentrates Market by Country
8.2.2 North America Plasma-derived Factor Concentrates Market by Country
8.3 North America Desmopressin & Fibrin Sealants Market by Country
8.4 North America Gene Therapy & Monoclonal Antibodies Market by Country
Chapter 9. North America Hemophilia Market by Country
9.1 US Hemophilia Market
9.1.1 US Hemophilia Market by Distribution Channel
9.1.2 US Hemophilia Market by Type
9.1.3 US Hemophilia Market by Treatment Type
9.1.4 US Hemophilia Market by Therapy
9.1.4.1 US Hemophilia Market by Factor Replacement Therapy Type
9.2 Canada Hemophilia Market
9.2.1 Canada Hemophilia Market by Distribution Channel
9.2.2 Canada Hemophilia Market by Type
9.2.3 Canada Hemophilia Market by Treatment Type
9.2.4 Canada Hemophilia Market by Therapy
9.2.4.1 Canada Hemophilia Market by Factor Replacement Therapy Type
9.3 Mexico Hemophilia Market
9.3.1 Mexico Hemophilia Market by Distribution Channel
9.3.2 Mexico Hemophilia Market by Type
9.3.3 Mexico Hemophilia Market by Treatment Type
9.3.4 Mexico Hemophilia Market by Therapy
9.3.4.1 Mexico Hemophilia Market by Factor Replacement Therapy Type
9.4 Rest of North America Hemophilia Market
9.4.1 Rest of North America Hemophilia Market by Distribution Channel
9.4.2 Rest of North America Hemophilia Market by Type
9.4.3 Rest of North America Hemophilia Market by Treatment Type
9.4.4 Rest of North America Hemophilia Market by Therapy
9.4.4.1 Rest of North America Hemophilia Market by Factor Replacement Therapy Type
Chapter 10. Company Profiles
10.1 Swedish Orphan Biovitrum AB (Investor AB)
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expenses
10.1.5 SWOT Analysis
10.2 Takeda Pharmaceutical Company Limited
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional Analysis
10.2.4 Research & Development Expense
10.2.5 Recent strategies and developments:
10.2.5.1 Trials and Approvals:
10.2.5.2 Product Launches and Product Expansions:
10.3 Pfizer, Inc.
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Regional & Segmental Analysis
10.3.4 Research & Development Expense
10.3.4.1 Partnerships, Collaborations, and Agreements:
10.3.4.2 Acquisition and Mergers:
10.4 CSL Limited (CSL Behring)
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Segmental and Regional Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Trials and Approvals:
10.4.5.2 Acquisition and Mergers:
10.4.6 SWOT Analysis
10.5 Octapharma AG
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Research & Development Expenses
10.5.4 Recent strategies and developments:
10.5.4.1 Trials and Approvals:
10.5.5 SWOT Analysis
10.6 Bayer AG
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental and Regional Analysis
10.6.4 Research & Development Expense
10.6.5 Recent strategies and developments:
10.6.5.1 Partnerships, Collaborations, and Agreements:
10.6.5.2 Acquisition and Mergers:
10.6.6 SWOT Analysis
10.7 F. Hoffmann-La Roche Ltd.
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Segmental and Regional Analysis
10.7.4 Research & Development Expense
10.7.5 SWOT Analysis
10.8 Novo Nordisk A/S
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Segmental & Regional Analysis
10.8.4 Research & Development Expenses
10.8.5 Recent strategies and developments:
10.8.5.1 Partnerships, Collaborations, and Agreements:
10.8.5.2 Product Launches and Product Expansions:
10.8.5.3 Acquisition and Mergers:
10.8.6 SWOT Analysis
10.9 BioMarin Pharmaceutical Inc.
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Regional Analysis
10.9.4 Research & Development Expenses
10.9.5 Recent strategies and developments:
10.9.5.1 Trials and Approvals:
10.9.6 SWOT Analysis
10.10. Sanofi S.A.
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Segmental and Regional Analysis
10.10.4 Research & Development Expense
10.10.5 Recent strategies and developments:
10.10.5.1 Trials and Approvals:
Unique Offerings 